212 related articles for article (PubMed ID: 18187929)
1. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
3. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
4. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
[TBL] [Abstract][Full Text] [Related]
5. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.
Singh L; Field MJ; Hughes J; Kuo BS; Suman-Chauhan N; Tuladhar BR; Wright DS; Naylor RJ
Eur J Pharmacol; 1997 Feb; 321(2):209-16. PubMed ID: 9063690
[TBL] [Abstract][Full Text] [Related]
6. Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets.
Furukawa TY; Nakayama H; Imazumi K; Yamakuni H; Takeshita K; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2014; 37(2):232-8. PubMed ID: 24492720
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting anti-emetic effect of T-2328, a novel NK(1) antagonist.
Watanabe Y; Okamoto M; Ishii T; Takatsuka S; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jun; 107(2):151-8. PubMed ID: 18544900
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
[TBL] [Abstract][Full Text] [Related]
10. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
11. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
Millan MJ; Dekeyne A; Gobert A; Mannoury la Cour C; Brocco M; Rivet JM; Di Cara B; Lejeune F; Cremers TI; Flik G; de Jong TR; Olivier B; de Nanteuil G
Eur Neuropsychopharmacol; 2010 Sep; 20(9):599-621. PubMed ID: 20483567
[TBL] [Abstract][Full Text] [Related]
12. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
13. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Darmani NA; Wang Y; Abad J; Ray AP; Thrush GR; Ramirez J
Brain Res; 2008 Jun; 1214():58-72. PubMed ID: 18471804
[TBL] [Abstract][Full Text] [Related]
14. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
Duffy RA; Varty GB; Morgan CA; Lachowicz JE
J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
[TBL] [Abstract][Full Text] [Related]
15. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist.
Ballard TM; Sänger S; Higgins GA
Eur J Pharmacol; 2001 Feb; 412(3):255-64. PubMed ID: 11166289
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
[TBL] [Abstract][Full Text] [Related]
20. The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs.
Kudlacz EM; Knippenberg RW; Shatzer SA; Kehne JH; McCloskey TC; Burkholder TP
J Auton Pharmacol; 1997 Apr; 17(2):109-19. PubMed ID: 9234081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]